ResMed stock performance snapshot
ResMed (RMD) has drawn investor attention after recent trading left the stock down about 9% over the past month and about 20% over the past 3 months, despite ongoing profitability and revenue generation.
See our latest analysis for ResMed.
That short term weakness sits alongside a year to date share price return that is down 15.13% and a 1 year total shareholder return that is down 15.45%, indicating that momentum has been fading rather than building.
If ResMed’s recent moves have you reassessing your portfolio, it may be a good moment to look at other healthcare technology opportunities through 29 healthcare AI stocks
With ResMed trading at US$207.78 and showing a value score of 5, alongside an indicated 30% discount to a US$270.60 analyst price target and intrinsic value estimates, is there a buying opportunity here or is the market already pricing in future growth?
Most Popular Narrative: 27.9% Undervalued
ResMed’s most followed narrative puts fair value at about $288.21 per share, compared with the recent $207.78 close, framing the current weakness as a sizeable discount that hinges on execution and cash flow delivery.
Acceleration in adoption of home-based, cloud-connected therapy solutions and digital health platforms (including software like Brightree and AirView) enhances recurring high-margin revenue streams and increases both user retention and net profit margins over time. Ongoing innovation in product development, including new releases of CPAP devices, mask interfaces, and integration of AI-driven features, strengthens ResMed's competitive differentiation and supports premium pricing power, driving both revenue and margin expansion.
Want to understand why this narrative backs a higher valuation? It leans on steadier top line growth, firm margins, and a richer future earnings multiple. The key is how those moving parts interact over time, not any single headline number.
Result: Fair Value of $288.21 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there is still a real risk that tighter reimbursement policies or faster adoption of alternative sleep therapies could pressure ResMed’s pricing power and margins.
Find out about the key risks to this ResMed narrative.
Next Steps
If the mix of recent share price pressure and an undervalued narrative has you torn, it helps to review the underlying rewards yourself. You can move quickly while the data is fresh by checking the 4 key rewards
Looking for more investment ideas?
If ResMed is on your radar, do not stop there. Broaden your watchlist with other stocks that could fit different roles in your portfolio.
- Target potential mispricings by scanning for companies that combine quality fundamentals with attractive entry points using the 54 high quality undervalued stocks.
- Reinforce your income stream by checking stocks that focus on higher yields and consistent payouts through the 12 dividend fortresses.
- Protect your downside by focusing on companies with steadier risk profiles using the 66 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com